Effects of zolmitriptan (Zomig(TM)) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine

Cephalalgia

Volumn 19, Issue 2, 1999, Pages 100-106

  Hughes, Andrew M ^a   Dixon, R ^a   Dane, A ^a   Kemp, J ^a   Cummings, L ^a   Yates, R A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cortical auditory evoked potential; Humans; Serotonin; Zolmitriptan

Indexed keywords

ZOLMITRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM;

ACOUSTIC STIMULATION; ADULT; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; REFERENCE VALUES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0032959306     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1999.019002100.x     Document Type: Article

References (31)

1. 1B/1D agonist an overview of efficacy Cephalalgia 1997;17 Suppl 18:28-40
2. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997;49:1210-8
3. Managing migraine. Drug Ther Bull 1998;36:41-4
4. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994;34:394-9
5. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997;17:153-8
6. 1B/1D agonist for migraine. Cephalalgia 1997;17 Suppl 18:4-14
7. Mills A, Rhodes P, Martin GR. (3H)311C90 binding sites in cat brain stem: implications for migraine treatment [Abstract]. Cephalalgia 1995;15 Suppl 14:116
8. Mazzotta G, Alberti A, Santucci A, Gallai V. The event-related potential P300 during headache-free period and spontaneous attack in adult headache sufferers. Headache 1995;35:210-5
9. Wang W, Schoenen J, Timsit-Berthier M. Cognitive functions in migraine without aura between attacks: a psychophysiological approach using the "oddball" paradigm. Neurophysiol Clin 1995;25:3-11
10. Reinsel R, Veselis R, Wronski M, Marino P. The 300 event-related potential during propofol sedation: a possible marker for amnesia? Br J Anaesth 1995;74:674-80
11. Schoenen J. Measuring central action of acute antimigraine drugs in humans. Cephalalgia 1997;17:12-6
12. Jasper H. The 10:20 electrode system of the international federation. Electroencephalogr Clin Neurophysiol 1958;10:371-5
13. Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol. In press
14. Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan. Effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Invest 1998;15:515-22
15. Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995;39:684-7
16. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2
17. Wang W, Schoenen J. Interictal potentiation of passive "oddball" auditory event-related potentials in migraine. Cephalalgia 1998;18:261-5
18. Drake M, Pakalnis A, Padamadan H. Long latency auditory event related potentials in migraine. Headache 1989;29:239-41
19. 1B/1D agonist zolmitriptan (311C90, Zomig™). Cephalalgia 1997;17:849-54
20. Hegeri U. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neuro-transmission: a new hypothesis. Biol Psychiatry 1993;33:173-87
21. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996;46:1404-9
22. Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug sumatriptan. Eur Neurol 1991;31:282-90
23. Rance D, Dallman L, Llewellyn E, Nuttall J, Verrier H. Use of Caco-2 cell monolayer model to assess the comparative absorption potential of electriptan and related antimigraine agents. Cephalalgia 1997;17:41B and poster presentation from 8th Congress of the International Headache Society
24. Hillyard S, Kutas M. Electrophysiology of cognitive processing. Annu Rev Physiol 1983;34:33-61
25. Pritchard W. Psychophysiology of P300. Psychol Bull 1981;89:506-40
26. Roth WT, Duncan CC, Pfefferbaum A, Timsit-Berthier M. Applications of cognitive ERPs in psychiatric patients. In: McCallum WC, Zappoli R, Denoth F, editors. Cerebral psychophysiology: event-related potentials (EEG suppl 38). Amsterdam: Elsevier, 1986:419-39
27. Jacobs BL, Azmitia EC. Structure and function of the brain serolonin system. Physiol Rev 1992;72:165-229
28. 1B receptors: in vivo microdialysis studies. J Neurochem 1997;69:2019-25
29. Duncan-Johnson CC, Donchin E. The P300 component of the event-related brain potential as an index of the information processing. Biol Psychol 1982;14:1-52
30. Dixon R, Hughes AM, Nairn K, Sellers M, Kemp JV, Yates RA. The effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers. Cephalalgia 1998;18:468-75
31. ABPI compendium of data sheets and summaries of product characteristics. Datapharm Publications Ltd, 1996-97